Gsa Capital Partners LLP Aldeyra Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	SELL	$3.25 - $4.72 $29,994 - $43,560	-9,229 Reduced 36.55%	16,020 $53,000
Q1 2024 May 03, 2024	SELL	$2.77 - $4.22 $397,533 - $605,629	-143,514 Reduced 85.04%	25,249 $82,000
Q4 2023 Feb 16, 2024	BUY	$1.47 - $6.06 $225,643 - $930,203	153,499 Added 1005.63%	168,763 $592,000
Q3 2023 Nov 15, 2023	SELL	$6.11 - $8.16 $393,746 - $525,854	-64,443 Reduced 80.85%	15,264 $101,000
Q2 2023 Aug 14, 2023	SELL	$7.11 - $11.89 $94,115 - $157,387	-13,237 Reduced 14.24%	79,707 $668,000
Q1 2023 May 12, 2023	SELL	$5.77 - $9.93 $290,023 - $499,121	-50,264 Reduced 35.1%	92,944 $922,000
Q4 2022 Feb 13, 2023	BUY	$5.08 - $7.09 $199,948 - $279,062	39,360 Added 37.9%	143,208 $997,000
Q3 2022 Nov 14, 2022	BUY	$3.8 - $7.74 $394,622 - $803,783	103,848 New	103,848 $555,000
Q2 2022 Aug 09, 2022	SELL	$2.43 - $4.85 $145,639 - $290,679	-59,934 Closed	0 $0
Q1 2022 May 11, 2022	SELL	$3.25 - $5.17 $215,085 - $342,150	-66,180 Reduced 52.48%	59,934 $266,000
Q4 2021 Feb 14, 2022	BUY	$3.5 - $9.63 $79,933 - $219,929	22,838 Added 22.11%	126,114 $504,000
Q3 2021 Nov 12, 2021	BUY	$7.94 - $11.31 $638,431 - $909,403	80,407 Added 351.6%	103,276 $907,000
Q2 2021 Aug 05, 2021	BUY	$10.44 - $14.85 $238,752 - $339,604	22,869 New	22,869 $259,000
Q1 2021 May 10, 2021	SELL	$6.53 - $14.42 $399,766 - $882,792	-61,220 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$6.31 - $8.13 $225,374 - $290,379	35,717 Added 140.05%	61,220 $420,000
Q3 2020 Nov 06, 2020	BUY	$4.0 - $7.53 $102,012 - $192,037	25,503 New	25,503 $189,000

117

36.4M

196K

142K

Ticker ALDX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 58,323,100
Market Cap $279M
Description
Aldeyra Therapeutics, Inc., a biotechnology company, develops and commercializes medicines for immune-mediated ocular and systemic diseases. The company's lead product candidate is reproxalap, a reactive aldehyde species (RASP)modulator, which is in Phase III clinical trial for the treatment of dry eye diseases and allergic conjunctivitis. It al...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.